Connect Tumour Lineage to the Next Clinical Decision
Endocrine and neuroendocrine tumours cross organ systems, specialties, and therapeutic platforms. This 2026 edition integrates lineage-based classification, functional biochemistry, pathology, molecular profiling, multimodality imaging, surgery, systemic therapy, and theranostics for clinicians managing rare and heterogeneous disease. It is written for endocrinology, oncology, pathology, nuclear medicine, radiology, gastroenterology, thoracic, and surgical teams.
The Lineage-to-Therapy Decision Atlas turns fragmented findings into an ordered plan by linking tumour identity, secretion, morphology, imaging phenotype, major mimics, decision pivots, and management anchors.
Use the book to strengthen these clinical capabilities:
• WHO 2025 taxonomy, differentiation, grade, and stage — preserve organ-specific meaning while building an integrated diagnosis
• Specimen handling, immunohistochemistry, Ki-67 assessment, and molecular testing — obtain decision-ready pathology from limited or heterogeneous tissue
• Hormone syndromes and dynamic endocrine testing — recognize physiological hazards, control confounders, and stabilize patients before definitive treatment
• CT, MRI, SSTR PET/CT, FDG PET/CT, and dual-tracer phenotyping — map anatomy, target expression, and aggressive discordant clones
• Pituitary, thyroid, parathyroid, adrenal, paraganglionic, pancreatic, gastrointestinal, thoracic, and rare primary tumours — apply site-specific diagnostic and management pathways
• Surgery, liver-directed therapy, ablation, targeted agents, chemotherapy, and PRRT — sequence treatment by biology, burden, tempo, organ reserve, and clinical need
• Hereditary predisposition, surveillance, symptom burden, nutrition, fertility, and survivorship — extend care from germline risk through long-term treatment effects
Use this multidisciplinary reference to move from an uncommon presentation to a defensible, patient-centered treatment sequence.